DISEASE |
SYMPTOMS |
Diabetic retinopathy |
Loss of vision |
Rheumatoid arthritis |
Pain and immobility from destroyed cartilage |
Atherosclerotic plaques |
Chest pain and dyspnoea |
Endometriosis |
Abdominal pain from intraperitoneal bleeding |
Crohn's disease |
Intestinal bleeding |
Psoriasis |
Persistent severe itching |
Uterine fibroids |
Vaginal bleeding and abdominal bleeding |
Benign prostatic hypertrophy |
Urinary retention |
Cancer |
Bleeding, thrombosis, anaemia. abdominal ascites, bone pain, seizures from cerebral oedema around the tumor and others |
Numerous angiogenesis inhibitors have received FDA approval for the treatment of cancer. VEGF, its receptor, or other particular molecules involved in angiogenesis were the focus of the majority of these targeted therapies. Among the approved inhibitors of angiogenesis are:
|
Hemorrhage, blood clots in the arteries that can lead to stroke or heart attack, hypertension, delayed wound healing, reversible posterior leukoencephalopathy syndrome, a brain condition, and protein in the urine are all potential side effects of VEGF-targeting angiogenesis inhibitor therapy. Additionally, fistulas and intestinal perforations seem to be uncommon side effects of several angiogenesis inhibitors.
The VEGF receptor-targeting anti-angiogenesis drugs also cause fatigue, diarrhea, biochemical hypothyroidism, hand-foot syndrome, heart failure, and hair abnormalities. |
EXOSOME THERAPY - CELLTIXCelltiX is a type of extracellular vesicle from Umbilical Cord-Derived Mesenchymal Stem Cells (MSCs) manufactured in a cGMP-compliant facility. It is a novel form of a major paracrine factor released by MSCs into a culture medium, which plays an important role in a wide range of biological processes.
|
STEM CELL THERAPY - CELLTIMAXCelltiMax is a product derived from human umbilical cord-derived Mesenchymal Stem Cells (MSCs). The cells are cultured, then administered to the patient via intramuscular or intravenous injection.
The cells have low immunogenicity making them safe, well-tolerated and free of side effects. They have the ability to differentiate into specialized cells with specific functions for various parts of the body, and can reduce inflammation, repair, renew, regenerate, and replace damaged cells. |
CRITERIAS |
STEM CELLS |
EXOSOMES |
Definition |
Stem cells are undifferentiated cells of the human body |
Extracellular vesicles, also known as exosomes, are the medical term for tiny bubbles that are released from stem cells. |
Function |
Unique, can become any type of cell, and they act as both building blocks and repair mechanisms in your body |
Extracellular vesicles, such as exosomes, carry genetic information and proteins to cells throughout your body. They also play a crucial role in creating paths for communication between cells, facilitating essential cell-to-cell interactions. |
Origins |
Donor stem cells are placed in your body and are guided into becoming specific cells in the body to replace and repair diseased cells |
Exosomes are extracted from donated human mesenchymal stem cells (MSCs) and then sterilized. |
Growth Factors |
Less amount of growth factors compared to exosomes |
Exosomes contain nearly three times the amount of growth factors. More growth factors mean a better ability to restore and revitalize target cells |
Administration |
• IV Stem Cell Therapy (Intravenous administration) • Intrathecal (directly into the spinal canal) • Site injections into problem areas (Knee, hips, hands, etc)• |
• Intravenous (IV) therapy • Direct injection in the treatment area |
STEM CELL THERAPY |
EXOSOME THERAPY |
Improve bodies' natural healing abilities |
High stabililty |
Modulate the immune system |
Low toxicity and immunogenicity |
Locate and reduce areas of inflammation |
High penetration |
Replace damaged and diseased cells |
Enhanced delivery efficiency |
Mesenchymal Stem Cells (MSCs) have been shown to alter the tumor microenvironment to reduce angiogenesis or neovascularization. In addition to causing tumor cells to die, MSCs can also limit angiogenesis by interacting with endothelial cells to cut off the flow of nutrients to the tumor cells.
According to a study, high concentrations of MSCs prevent the growth of blood vessels by releasing reactive oxygen species (ROS), whereas low concentrations of MSCs can encourage the growth of blood vessels in tumors by secreting proangiogenic substances and developing into pericytes. Diagram A shows the gross image and histological analysis of Gil36 and Gil36/MSC co-cultured tumor section while diagram B displays the scheme of anti-angiogenesis of MSC when co-cultured with Gli36 cell. Lastly, diagram C shows the schematic figure of capillary degeneration induced by connexin-43 gap junctional channel between MSC and endothelial cell. |
The tumor anti-angiogenesis processes induced by mesenchymal stem cell (MSC)
|
CELL TISSUE TECHNOLOGY SDN BHD
Malaysia's FIRST Tissue Engineering Firm |
|